RxDoctor Payments Data

Joel Nizin, MD

Colon & Rectal Surgery · Ridgewood, NJNPI 1972599025

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 28.1% of the total. Reporting peaked in 2021 at $149 and has fallen 88.1% since, to $18 in 2024. That places this record below the midpoint for colon & rectal surgery clinicians in NJ, where the typical reported total is $1,276.

$406in general payments, 2019–2025

Across 27 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$114
  • Braintree Laboratories, Inc.$75
  • Takeda Pharmaceuticals U.S.A., Inc.$57
  • Ardelyx, Inc.$33
  • AbbVie$32
  • Davol Inc.$28
  • plus $67 from 3 others

What the payments were for

  • Food & beverage$406100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$406 in reported general payments places this provider in the 30th percentile of 86 colon & rectal surgery providers in New Jersey.

See all colon & rectal surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$149,390
Medicare patients
506
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine53$16,911
LinzessLinaclotide14$8,918
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine22$1,851
ErythromycinErythromycin Base17$239
Pantoprazole Sodium20$174
Neomycin Sulfate17$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$32$8,91814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 86 colon & rectal surgery providers in New Jersey.

Other colon & rectal surgery in Ridgewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →